ImpediMed

ImpediMed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of ImpediMed (IPD.AX) as of Sep 27, 2026 is 80.69 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 67.28 % — a change of 19.93% (higher).

FCF Conversion

80.69 %

YoY

19.93%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ImpediMed is 2026 80.69 % . FCF Conversion Rate (FCF/EBITDA) of ImpediMed was 2025 67.28 % . It decreases by 19.93% higher compared to the previous year.

The ImpediMed FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
81.77 AUD
Jan 1, 2020
100.01 AUD
Jan 1, 2021
75.90 AUD
Jan 1, 2022
105.09 AUD
Jan 1, 2023
117.40 AUD
Jan 1, 2024
105.58 AUD
Jan 1, 2025
67.28 AUD
Jan 1, 2026
80.69 AUD
The ImpediMed FCF Conversion history
YEARFCF ConversionYoY
80.69 %+19.93%
67.28 %-36.27%
105.58 %-10.07%
117.40 %+11.72%
105.09 %+38.46%
75.90 %-24.11%
100.01 %+22.30%
81.77 %-5.64%
86.66 %-7.75%
93.94 %+8.32%
86.72 %+17.85%
73.59 %-14.56%
86.12 %—
Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

FCF Conversion Rate (FCF/EBITDA) of ImpediMed is 80.69 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of ImpediMed changed from 67.28 % to 80.69 %, representing a 19.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — ImpediMed

All Key Metrics — ImpediMed